KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Boston Scientific (BSX) Revenue (2016 - 2025)

Boston Scientific's Revenue history spans 17 years, with the latest figure at $5.3 billion for Q4 2025.

  • For Q4 2025, Revenue rose 15.87% year-over-year to $5.3 billion; the TTM value through Dec 2025 reached $20.1 billion, up 19.87%, while the annual FY2025 figure was $20.1 billion, 19.87% up from the prior year.
  • Revenue for Q4 2025 was $5.3 billion at Boston Scientific, up from $5.1 billion in the prior quarter.
  • Across five years, Revenue topped out at $5.3 billion in Q4 2025 and bottomed at $2.8 billion in Q1 2021.
  • The 5-year median for Revenue is $3.6 billion (2023), against an average of $3.8 billion.
  • The largest annual shift saw Revenue surged 53.62% in 2021 before it increased 3.68% in 2022.
  • A 5-year view of Revenue shows it stood at $3.1 billion in 2021, then rose by 3.68% to $3.2 billion in 2022, then grew by 14.9% to $3.7 billion in 2023, then increased by 22.44% to $4.6 billion in 2024, then increased by 15.87% to $5.3 billion in 2025.
  • Per Business Quant, the three most recent readings for BSX's Revenue are $5.3 billion (Q4 2025), $5.1 billion (Q3 2025), and $5.1 billion (Q2 2025).